Lexology July 24, 2024
Venable LLP

On July 19, 2024, the FDA approved the second biosimilar of Alexion / AstraZeneca’s Soliris® (eculizumab), Samsung Bioepis’s Epysqli® (eculizumab-aagh), approximately one year after Samsung Bioepis announced the FDA acceptance of its aBLA. Epysqli® was approved as an interchangeable. The FDA previously approved Amgen’s Bkemv™ (eculizumab-aeeb) as an interchangeable to Soliris® in May 2024 (previously reported FDA Approves First Interchangeable Biosimilar of Alexion’s Soliris® (eculizumab) – Amgen’s Bkemv™ (eculizumab-aeeb)). Like Bkemv™, Epysqli® was approved with a skinny label for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Samsung Bioepis currently has five instituted IPRs (IPR2023-00933, IPR2023-00998, IPR2023-00999, IPR2023-01069, IPR2023-01070) and a pending BPCIA litigation...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA
Trump's FDA Pick Is MedPage Today's Former Top Editor

Share This Article